PRME

Prime Medicine, Inc. is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing platform. Headquartered in Cambridge, Massachusetts, the company was founded in 2019 by pioneering scientists including Dr. David Liu from the Broad Institute. Prime Medicine's technology enables precise, targeted genetic edits without requiring double-strand DNA breaks, potentially offering advantages over traditional CRISPR methods. The company's pipeline addresses genetic diseases across multiple therapeutic areas, including hematology, immunology, liver diseases, and ocular conditions. Lead programs include treatments for chronic granulomatous disease and sickle cell disease. Prime Medicine operates research and development facilities in Cambridge and employs approximately 200 people as of 2024. The company completed its initial public offering in October 2022, raising approximately $170 million. In 2023, Prime Medicine expanded its intellectual property portfolio and advanced multiple preclinical programs toward IND-enabling studies. The company collaborates with academic institutions and maintains strategic partnerships to accelerate development of its Prime Editing platform. Prime Medicine competes in the gene editing sector alongside companies developing CRISPR, base editing, and other genetic modification technologies. The company focuses on both in vivo and ex vivo therapeutic approaches, with an emphasis on diseases where precise genetic correction could provide transformative benefits for patients with limited treatment options.